New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
09:59 EDTDCIN, KING, FELE, CLGX, HSH, VOLC, DOV, NVDA, PRMW, PODD, CSII, NYMT, EAC, AAPL, SPNC, KERX, DXCMOn The Fly: Analyst Initiation Summary
Apple (AAPL) initiated with an Outperform at Macquarie... Cardiovascular Systems (CSII) initiated with a Strong Buy at Needham... DexCom (DXCM) initiated with a Neutral at Sterne Agee... Erickson Air-Crane (EAC) initiated with a Hold at Canaccord... Insulet (PODD) initiated with a Buy at Sterne Agee... Keryx (KERX) initiated with a Buy at Mizuho... New York Mortgage (NYMT) initiated with a Buy at UBS... Primo Water (PRMW) initiated with a Buy at B. Riley... Spectranetics (SPNC) initiated with a Buy at Needham... Tandem Diabetes (TNDM) initiated with a Neutral at Sterne Agee... Volcano (VOLC) initiated with a Hold at Needham... Franklin Electric (FELE) initiated with a Hold at Gabelli... NVIDIA (NVDA) initiated with an Underperform at CLSA... Hillshire Brands (HSH) initiated with an Equal Weight at Stephens... King Digital (KING) coverage initiated at Sterne Agee... Dover (DOV) initiated with a Neutral at Goldman... CoreLogic (CLGX) initiated with an Outperform at Oppenheimer... Digital Cinema (DCIN) initiated with a Speculative Buy at Benchmark Co.
News For AAPL;CSII;DXCM;EAC;PODD;KERX;NYMT;PRMW;SPNC;VOLC;FELE;NVDA;HSH;KING;DOV;CLGX;DCIN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 5, 2014
10:00 EDTDOVOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTAAPLActive equity options trading
Subscribe for More Information
09:28 EDTDOVDover downgraded at BofA/Merrill
As previously reported, Bofa/Merrill downgraded Dover to Neutral from Buy. The analyst expects Dover's upstream exposure to be a headwind in 2015 given the growing risks from a slowdown in global drilling and completion spending. Price target to $85 from $93.
09:19 EDTKERXKeryx initiated with an Outperform at Cowen
Subscribe for More Information
07:45 EDTAAPLConsensus on Apple iPhone units could be low, says UBS
Subscribe for More Information
07:30 EDTDOVDover downgraded to Neutral from Buy at BofA/Merrill
06:41 EDTAAPLApple questions validity of plaintiffs in iPod case, NY Times says
Subscribe for More Information
06:03 EDTAAPLiOS mobile traffic shows iPhone 6 launch strong, says Piper Jaffray
Piper Jaffray says that according to Quantcast data, Apple's (AAPL) iOS mobile traffic share increased from 60.6% at iPhone 6 launch to 61.4% nine weeks after launch, while Google's (GOOG) Android decreased from 38.4% to 37.5% in the same period. Piper views the iOS mobile traffic share as further evidence that the iPhone 6 launch in the U.S. is off to a strong start. It keeps an Overweight rating on Apple shares with a $135 price target.
December 4, 2014
16:00 EDTAAPLOptions Update; December 4, 2014
Subscribe for More Information
09:37 EDTAAPLActive equity options trading
Active equity options trading according to Track Data: AAPL ALTR P BIDU AMZN TSLA X NFLX TWTR WMT
07:41 EDTKERXKeryx issued new U.S. patent for Auryxia
Keryx Biopharmaceuticals announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,901,349 on December 2. The patent, which expires in 2024, claims a method of treating hyperphosphatemia comprising administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject, wherein the orally administrable form is prepared from a ferric citrate having a BET active surface area greater than about 16 sq. m/g. The patent also claims a broad category of orally administrable forms covering Auryxia, as well as other oral formulations that could be developed in the future. On September 5, Auryxia was approved by the FDA for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. This newly issued patent further enhances the company's key patent family, which includes U.S. Patent Nos. 7,767,851, 8,299,298, 8,338,642, 8,609,896, 8,754,257, 8,754,258, and 8,846,976 which expire in 2024, and U.S. Patent No. 8,093,423, which expires in 2026, before patent term extension. Each of these patents contains composition and method of use claims covering Auryxia.
07:40 EDTSPNCSpectranetics sees Stellarex DCB acquisition to provide growth catalyst in 2015
Subscribe for More Information
07:40 EDTSPNCSpectranetics sees FY15 EPS (20c)-(10c), consensus (12c)
Sees FY15 revenue $258M-$265M, consensus $274.36M. 2015 projected revenue includes reduced revenue in the range of $1.5M-$2M, or approximately 1%, due to the declining exchange rate of euros in relation to U.S. dollars. Vascular Intervention revenue growth is anticipated to be in the range of 41% to 46%. This includes AngioSculpt revenue of $62M-$66M and ISR revenue of approximately $15M-$20M. EBITDA is anticipated to be in the range of $12.3 million to $16.3 million. Gross margin is expected to increase by 50 to 100 basis points in 2015. Gross margin guidance for 2014 is 74.5% to 75%. Research, development and other technology expenses are expected to be approximately 15.5% to 16.0% of revenue, an increase over 2014 guidance of 14.5%, based on continued product development and clinical trial investments.
07:37 EDTSPNCSpectranetics targeting $15M-$20M of ISR-related revenue in 2015
Subscribe for More Information
December 3, 2014
16:14 EDTFELEFranklin Electric to close Wittlich, Germany manufacturing facility
Franklin Electric announced a plan to close its Wittlich, Germany manufacturing facility and complete other asset write-offs, miscellaneous realignments and fixed costs reductions in other European based business units and facilities. As part of this action, the company will transfer the existing Wittlich manufacturing activity primarily to its Brno, Czech Republic facility. The company had initially estimated the costs of this action to be between $13.2M-$14M. The company now estimates the pretax charge for these actions to be approximately $19.4M. The charges, which include severance expenses, professional service fees, asset write-offs, and temporarily leased facilities costs, began in Q3 and are now projected to conclude by the end of 2015, with the majority of charges to be incurred prior to the end of 2Q15. The increase in estimated costs is entirely due to higher payments for severance and other employee separation costs. Approximately ten percent of these charges will be non-cash. Finally, the company estimates these charges will have a payback period of approximately 5 years, mostly as a result of direct labor and facility savings.
16:00 EDTAAPLOptions Update; December 3, 2014
iPath S&P 500 VIX Short-Term Futures down 45c to 26.52. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX C GILD RIG ABX according to Track Data.
09:35 EDTAAPLActive equity options trading
Subscribe for More Information
09:23 EDTAAPLOn The Fly: Pre-market Movers
Subscribe for More Information
08:05 EDTAAPLApple price target raised to $150 from $135 at JMP Securities
Subscribe for More Information
07:09 EDTCSIIPiper Jaffray to hold a conference
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use